- Home »
- Quarterly Results »
- Natco Pharma Q1 Results Revenue Reaches ₹13,626 Million with Profit of ₹6,685 Million
Natco Pharma Q1 Results Revenue Reaches ₹13,626 Million with Profit of ₹6,685 Million
Natco Pharma Q1 Results indicate a revenue increase of 27.3% QoQ to ₹13,626 million, while Natco Pharma Q1 Results also reveal a profit for the period rising 73.5% YoY to ₹6,685 million.
by P Nandhini
Updated Sep 20, 2024
Table of Content
Natco Pharma Q1 Results: Natco Pharma declared its Q1 results for 2024-2025 on June 30, 2024, showcasing a significant growth in revenue. The company reported a revenue from operations of ₹13,626 million, which is a remarkable increase of 27.3% compared to the previous quarter's revenue of ₹10,683 million.
This quarter-over-quarter (QoQ) growth highlights Natco’s strong performance in the pharmaceutical sector, particularly in branded oncology and specialty drugs. In addition to revenue growth, Natco Pharma's profit before tax also surged to ₹8,036 million, marking a 68.7% increase QoQ from ₹4,776 million in the last quarter.
The company achieved a profit of ₹6,685 million for this period, reflecting a year-over-year (YoY) rise as well. Overall, Natco's Q1 results indicate a strong start to the financial year, with impressive increases in both revenue and profit, underscoring its focus on delivering affordable, complex medicines in a competitive market.
For More Q1 results check our Twitter Page
Natco Pharma Q1 Results 2024 - 2025
Here are the key figures from Natco Pharma's Q1 Results for 2024-2025. The data highlights the company’s strong performance in revenue and profit growth, demonstrating its effective strategies in the pharmaceutical market.
| Particulars | Q1 2024-2025 (₹ in millions) | Q4 2023-2024 (₹ in millions) | QoQ Change (%) |
|---|---|---|---|
| Revenue from operations | 13,626 | 10,683 | 27.3 |
| Other income | 481 | 420 | 14.5 |
| Total income | 14,107 | 11,103 | 27.0 |
| Cost of materials consumed | 1,513 | 1,276 | 18.5 |
| Total expenses | 6,071 | 6,327 | -4.0 |
| Profit before tax | 8,036 | 4,776 | 68.7 |
| Tax expense | 1,351 | 913 | 47.9 |
| Profit for the period | 6,685 | 3,863 | 73.5 |
| Total comprehensive income | 6,541 | 3,738 | 74.8 |
| Earnings per share (Basic) | 37.32 | 21.56 | 73.3 |
Source: Click Here
Natco Pharma Current Market Overview
Natco Pharma is currently performing well in the stock market, with a share price of ₹1,518 and a market capitalization of ₹27,181 crore. The company's stock has seen a high of ₹1,639 and a low of ₹724 over the past year, showing some volatility.
With a price-to-earnings (P/E) ratio of 16.6, Natco appears to be reasonably valued compared to its earnings. The company also offers a dividend yield of 0.63%, making it attractive to investors looking for income.
Additionally, strong return metrics like a return on capital employed (ROCE) of 30.1% and a return on equity (ROE) of 25.9% indicate that Natco is effectively using its resources to generate profits. Overall, Natco Pharma is in a solid position in the market.
| Metric | Value |
|---|---|
| Current Price | ₹1,518 |
| Market Capitalization | ₹27,181 Cr. |
| High/Low Price | ₹1,639 / ₹724 |
| Stock P/E Ratio | 16.6 |
| Book Value | ₹327 |
| Dividend Yield | 0.63% |
| Return on Capital Employed (ROCE) | 30.1% |
| Return on Equity (ROE) | 25.9% |
| Face Value | ₹2.00 |
Quarterly Results
Here are the quarterly results for Natco Pharma for the last three quarters: December 2023, March 2024, and June 2024. These figures showcase the company’s financial performance, highlighting trends in sales, expenses, and profits.
| Metric | Dec 2023 (₹ Crores) | Mar 2024 (₹ Crores) | Jun 2024 (₹ Crores) |
|---|---|---|---|
| Sales | 759 | 1,068 | 1,363 |
| Expenses | 490 | 571 | 558 |
| Operating Profit | 268 | 497 | 805 |
| Operating Profit Margin (OPM) % | 35% | 47% | 59% |
| Net Profit | 213 | 386 | 668 |
| Earnings Per Share (EPS) | 11.88 | 21.57 | 37.32 |
About Natco Pharma
Natco Pharma is an Indian pharmaceutical company based in Hyderabad. It focuses on making affordable medicines, especially in areas like oncology, cardiology, and diabetes. Established in 1981, Natco specializes in producing complex drugs and active pharmaceutical ingredients.
The company is known for its commitment to quality and innovation, aiming to improve healthcare access for patients. With a strong presence in both domestic and international markets, Natco Pharma continues to expand its product range and contribute to the global pharmaceutical industry.
Check our website for more Q1 results.
Natco Pharma Q1 Results - FAQs
1. What were the revenue figures for Natco Pharma in Q1 2024-2025?
Natco Pharma reported a revenue from operations of ₹13,626 million.
2. How much did Natco Pharma’s revenue increase compared to the previous quarter?
Natco Pharma's revenue increased by 27.3% compared to the previous quarter.
3. What was Natco Pharma's profit before tax in Q1 2024-2025?
Natco Pharma's profit before tax was ₹8,036 million.
4. What percentage increase did Natco Pharma achieve in profit before tax?
Natco Pharma achieved a 68.7% increase in profit before tax compared to the last quarter.
5. What is the profit for the period reported by Natco Pharma?
Natco Pharma reported a profit of ₹6,685 million for the period.
6. What was the total income reported by Natco Pharma?
Natco Pharma reported a total income of ₹14,107 million.
7. What were Natco Pharma’s total expenses in Q1 2024-2025?
Natco Pharma's total expenses were ₹6,071 million.
8. What is the basic earnings per share (EPS) for Natco Pharma?
The basic EPS for Natco Pharma is ₹37.32.
9. How much other income did Natco Pharma report?
Natco Pharma reported other income of ₹481 million.
10. What was Natco Pharma’s total comprehensive income for Q1 2024-2025?
Natco Pharma's total comprehensive income was ₹6,541 million.